報價延遲最少15分鐘:2024/12/23 22:24 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.388 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.52/-1.00
|
|
企業價值
18.64M
|
| 資產負債 |
|
每股賬面淨值
-0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
14.92M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:24 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. |